Murielle Lortie Profound Medical (NASDAQ:PROF; TSX:PRN) appointed financial executive, Murielle Lortie, as a director, effective immediately. Ms. Lortie is the CFO of Liminal Biosciences, a Nasdaq-listed, clinical-stage...
Brian O’Callaghan ObsEva (NASDAQ:OBSV) appointed Brian O’Callaghan as CEO, effective Dec. 1. He succeeds ObsEva’s co-founder, Ernest Loumaye, M.D., Ph.D., who is retiring from his role as CEO but will remain a...
Marizyme (NASDAQ:MRZM) appointed Neil Campbell, Ph.D., as CEO, replacing executive chairman James Sapirstein, who has been the company’s interim CEO since September 2020. Dr. Campbell currently serves as chairman of...
LogicBio Therapeutics (NASDAQ:LOGC) appointed Mariana Nacht, Ph.D., as CSO, effective Nov. 30; and promoted Kyle Chiang, Ph.D., to the role of COO, effective Nov. 2. The company is expanding its leadership team to...
Aethlon Medical (NASDAQ:AEMD) appointed Charles Fisher, M.D., as CEO, effective Oct. 30. Dr. Fisher joined Aethlon as a member of its board and served as its chairman since November 2017. He succeeds Dr. Timothy Rodell...
Randy Maddux iBio (NYSE AMERICAN:IBIO) appointed biotech industry veteran, Randy Maddux, as COO, effective Dec. 1. Mr. Maddux has more than 20 years of global biologics drug development and manufacturing, business...
Brad Hauser Soliton (NASDAQ:SOLY) named Brad Hauser as president and CEO as the company prepares for its commercial launch. Mr. Hauser most recently was VP of R&D and general manager for CoolSculpting at Allergan...
William Fanslow Closely-held Fibrocor Therapeutics appointed industry veteran, William Fanslow Ph.D., as SVP of drug development. Dr. Fanslow has more than 20 years of experience in drug development, including both...
Perimeter Medical Imaging AI (TSXV:PINK; FSE:4PC) appointed Jeremy Sobotta as its new CEO and Tom Boon as its new COO, effective immediately. Mr. Sobotta was most recently Perimeter’s CFO and replaces Tom Boon as CEO...
Gary Sender iBio (NYSE AMERICAN:IBIO) appointed senior financial executive, Gary Sender, as a director and a member of the board’s compensation committee. In addition, Mr. Sender was appointed chair of iBio’s audit...